Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High-dose Melphalan and Autologous Stem Cell Transplantation

Multiple myeloma (MM) is the second most common hematologic malignancy, with a yearly incidence of approximately 700 cases in Sweden (1). Even with commonly occurring disease manifestations, there is a large variance in the combination of symptoms, signs, and clinical outcomes. Over the last 20 years, there has been a radical improvement in the treatment results, which is partially due to the development of several new effective drugs (2). Similar to other malignant diseases, genetic aberrations that are potential high-risk markers for more aggressive MM have been identified (3).

Source: Experimental Hematology - February 17, 2021 Category: Hematology Authors: Ljupco Veskovski, Per-Ola Andersson, Ingemar Turesson, Daniel Malmodin, Anders Pedersen, Ulf-Henrik Mellqvist Source Type: research